PAULA GARCÍA SAN JOSÉ-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Prevalence of Systemic Hypertension and Control of Systolic Blood Pressure in a Cohort of 14 Dogs with Adrenal-Dependent Hypercortisolism during the First Year of Trilostane Treatment or after Adrenalectomy

    Animals, Vol. 14, Núm. 3

2022

  1. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate

    Veterinary and Comparative Oncology, Vol. 20, Núm. 1, pp. 179-188

  2. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane

    Veterinary Record, Vol. 191, Núm. 3, pp. no

2021

  1. Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment

    Journal of Veterinary Internal Medicine, Vol. 35, Núm. 1, pp. 130-141

  2. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia

    New Zealand Veterinary Journal, Vol. 69, Núm. 4, pp. 234-239

2020

  1. Prevalence and risk factors associated with systemic hypertension in dogs with spontaneous hyperadrenocorticism

    Journal of Veterinary Internal Medicine, Vol. 34, Núm. 5, pp. 1768-1778

2016

  1. Diagnóstico del hipoadrenocorticismo canino y felino

    Argos: Informativo Veterinario, Núm. 183, pp. 40-43